Roche Korea's brinkmanship tactics draws criticism

Published: 2008-02-29 07:00:00

Updated: 2008-02-29 07:00:00

Roche Korea, a Korean branch of Swiss based multination drugmaker, is under fire for allegedly raising the insurance price Fuzeon (enfuvirtide), new class of AIDS drugs.

Fuzeon works by preventing the AIDS virus from invading the white blood cells that are the primary targets of HIV. By contra...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK